· rebuilt nightly from public records
Signal Sheet
New York, New York is home to iBio, a publicly listed pharmaceutical preparations company. It raised $26M in Jan 2026 and its filings name 10 officers. Everything below links to the record it came from.
The easy button for new customers
Lakewave's AI keeps accounts like this one coming. Your pipeline refills while you sleep.
Every night it scans funding, filings, new officers, hiring, contracts, permits and bids, finds the accounts that fit what you sell, and delivers each with outreach and a pursuit plan. Just need a list? Its AI waterfall builds one with verified, reachable contacts.
The roles that matter for a seller right now. Names on this page come from SEC filings or the company's own announcements. Contacts you find with a free trial are verified before you see them. How we source names
| Role | Contact | Source | Why they matter now |
|---|---|---|---|
| Executive Officer | Martin A. Brenner | SEC filing, Jan 2026 | Named officer in the filing; part of the buying group |
| Executive Officer | Felipe Duran | SEC filing, Jan 2026 | Named officer in the filing; part of the buying group |
| Executive Officer | Marc Banjak | SEC filing, Jan 2026 | Named officer in the filing; part of the buying group |
| Chief Technology Officer | Evert Shimmelpennink | SEC filing, Jan 2026 | Technology and tooling decisions |
| Chief Technology Officer | Alexandra Kropotova | SEC filing, Jan 2026 | Technology and tooling decisions |
| Chief Technology Officer | William Clark | SEC filing, Jan 2026 | Technology and tooling decisions |
| Chief Technology Officer | Gary Sender | SEC filing, Jan 2026 | Technology and tooling decisions |
| Chief Technology Officer | David Arkowitz | SEC filing, Jan 2026 | Technology and tooling decisions |
| Chief Technology Officer | Antonio Parada | SEC filing, Jan 2026 | Technology and tooling decisions |
| Chief Technology Officer | Alexandra Kroptova | SEC filing, Apr 2025 | Technology and tooling decisions |
Officer or director change
New leadershipEquity raise reported to the SEC, Jan 2026. Money arrives before the spending plan does.
Capital2 equity raises in 9 months. Repeat funding is a company buying for growth, not maintenance.
PatternThe most recent events first, refreshed every night. Each links to the record it came from.
| When | What happened | Kind | Source |
|---|---|---|---|
| Oct 14, 2026 | Officer or director change | New leadership | SEC filing |
| Jul 31, 2026 | Officer or director change | New leadership | SEC filing |
| Jan 8, 2026 | Raised $26M in equity from 7 investors | Capital | SEC filing |
| Apr 29, 2025 | Raised $11.1M in equity from 5 investors | Capital | SEC filing |
Lakewave finds the right people at iBio, checks every address against the mail server before you see it, and drafts a first email for each, which you review and send from your own inbox.
Try it on iBio with a free trial →| Headquarters | New York, New York, per the filing address |
| Industry group | Pharmaceutical Preparations |
| Ownership | Listed company |
| Raise history | $11.1M (Apr 2025) · $26M (Jan 2026) |
| Lakewave Rising | 11 · 2 kinds of evidence · rank in New York after sign-up |
Private-sector companies in the same industry group and state, ranked by Rising score.
Yes. iBio reported a $26M equity raise to the SEC on Jan 8, 2026 with 7 investors.
The company's SEC filing, Jan 2026 names Martin A. Brenner (Executive Officer) among its officers.
New York, New York, per the address on its SEC filing.
Select the accounts and territory you sell to and get dated reasons for every company: new budget, new leaders, new hires, with who to reach and a first draft for each contact.
Start your free trialCompiled from public records and refreshed nightly; last updated Nov 16, 2026. Facts are as the SEC, the company's careers page or the company's own announcements published them. Check the source before acting. See something wrong? Tell us and we will correct it.